MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Abeona Therapeutics Inc

Fechado

4.67 4.71

Visão Geral

Variação de preço das ações

24h

Atual

Mín

4.41

Máximo

4.9

Indicadores-chave

By Trading Economics

Funcionários

136

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+298.93% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

4.4M

218M

Abertura anterior

-0.04

Fecho anterior

4.67

Abeona Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

22 de abr. de 2024, 23:00 UTC

Grandes Movimentos do Mercado

Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter

Comparação entre Pares

Variação de preço

Abeona Therapeutics Inc Previsão

Preço-alvo

By TipRanks

298.93% parte superior

Previsão para 12 meses

Média 18.67 USD  298.93%

Máximo 25 USD

Mínimo 15 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Abeona Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

3 ratings

3

Comprar

0

Manter

0

Vender

Informação Financeira

$

Sobre Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.